Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.

Everson G, Lasseter KC, Anderson KE, Bauer LA, Carithens RL Jr, Wilner KD, Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ.

Br J Clin Pharmacol. 2000;49 Suppl 1:21S-26S.

2.

The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.

Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, Turncliff RZ.

Br J Clin Pharmacol. 2000;49 Suppl 1:27S-33S.

3.

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.

Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA, Hansen RA.

Br J Clin Pharmacol. 2000;49 Suppl 1:15S-20S.

4.

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers.

Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A.

Br J Clin Pharmacol. 2000;49 Suppl 1:65S-70S.

5.

Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.

Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N.

Br J Clin Pharmacol. 2000;49 Suppl 1:5S-13S.

6.

Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.

Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL.

Clin Pharmacokinet. 2008;47(8):533-42.

PMID:
18611062
7.

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.

Miceli JJ, Smith M, Robarge L, Morse T, Laurent A.

Br J Clin Pharmacol. 2000;49 Suppl 1:71S-76S.

8.

The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B.

Br J Clin Pharmacol. 2002;53 Suppl 1:21S-30S.

9.

The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid.

Wilner KD, Hansen RA, Folger CJ, Geoffroy P.

Br J Clin Pharmacol. 2000;49 Suppl 1:57S-60S.

10.

Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients.

Reyes JF, Vargas R, Kumar D, Cullen EI, Perdomo CA, Pratt RD.

Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:9-17.

11.

An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.

Baird-Bellaire S, Behrle JA, Parker VD, Patat A, Paul J, Nichols AI.

Clin Ther. 2013 Jun;35(6):782-94. doi: 10.1016/j.clinthera.2013.03.013. Epub 2013 Apr 25.

PMID:
23623756
12.

Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.

Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M.

Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.

PMID:
23208320
13.

Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.

Grasela DM, Christofalo B, Kollia GD, Duncan G, Noveck R, Manning JA Jr, LaCreta FP.

Pharmacotherapy. 2000 Jun;20(6 Pt 2):87S-94S.

PMID:
10850525
14.

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.

Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H.

Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015.

PMID:
20110053
15.

Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.

Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG.

J Clin Pharmacol. 2005 Jun;45(6):620-30.

PMID:
15901743
16.

Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.

Bauman JW, Antal JM, Adams LM, Johnson BM, Murray SC, Peng B, Kirby LC, Lebowitz PF, Marbury TC, Swan S, Gutierrez M.

Invest New Drugs. 2012 Apr;30(2):662-71. doi: 10.1007/s10637-010-9604-2. Epub 2010 Dec 29.

PMID:
21188466
17.

Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.

Baririan N, Van Obbergh L, Desager JP, Verbeeck RK, Wallemacq P, Starkel P, Horsmans Y.

Clin Pharmacokinet. 2007;46(3):261-70.

PMID:
17328584
18.

An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function.

Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT.

Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:51-5.

19.

The effect of food on the absorption of oral ziprasidone.

Miceli JJ, Glue P, Alderman J, Wilner K.

Psychopharmacol Bull. 2007;40(3):58-68.

PMID:
18007569
20.

Effect of moderate liver impairment on the pharmacokinetics of opicapone.

Rocha JF, Santos A, Falcão A, Lopes N, Nunes T, Pinto R, Soares-da-Silva P.

Eur J Clin Pharmacol. 2014 Mar;70(3):279-86. doi: 10.1007/s00228-013-1602-9. Epub 2013 Nov 24.

PMID:
24271646

Supplemental Content

Support Center